Elekta AB (publ) (OTCMKTS:EKTAY - Get Free Report) is expected to be announcing its Q4 2025 earnings results before the market opens on Wednesday, May 28th. Analysts expect the company to announce earnings of $0.13 per share and revenue of $507.19 million for the quarter.
Elekta AB (publ) (OTCMKTS:EKTAY - Get Free Report) last issued its earnings results on Wednesday, May 28th. The company reported $0.11 earnings per share for the quarter, missing analysts' consensus estimates of $0.13 by ($0.02). Elekta AB (publ) had a return on equity of 11.07% and a net margin of 5.65%. The business had revenue of $503.22 million for the quarter, compared to the consensus estimate of $507.19 million. On average, analysts expect Elekta AB (publ) to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Elekta AB (publ) Price Performance
OTCMKTS EKTAY traded up $0.08 during trading hours on Thursday, hitting $5.49. The company had a trading volume of 3,809 shares, compared to its average volume of 17,671. The firm has a 50 day simple moving average of $5.06 and a 200 day simple moving average of $5.47. The company has a debt-to-equity ratio of 0.60, a quick ratio of 0.81 and a current ratio of 1.05. Elekta AB has a 52 week low of $4.36 and a 52 week high of $8.17. The firm has a market capitalization of $2.11 billion, a price-to-earnings ratio of 21.96 and a beta of 1.26.
Wall Street Analysts Forecast Growth
Separately, Sanford C. Bernstein raised shares of Elekta AB (publ) from a "strong sell" rating to a "hold" rating in a research report on Wednesday, January 29th.
View Our Latest Stock Analysis on Elekta AB (publ)
About Elekta AB (publ)
(
Get Free Report)
Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services.
Recommended Stories

Before you consider Elekta AB (publ), you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elekta AB (publ) wasn't on the list.
While Elekta AB (publ) currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.